Innovent Biologics
IPO
- Headquarters
- Suzhou
- Employees
- 5001–10000
- Founded
- 2011
- Business Model
- B2B
- Website
- en.innoventbio.com
- Total Funding
- $475.0M
- Last Round
- $80.0M Venture RoundJan 2025
About
Innovent Biologics (HKEX: 01801) is a leading biopharmaceutical company founded in 2011 and headquartered in Suzhou Industrial Park, Jiangsu, China. The company is dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for oncology, metabolic diseases, autoimmune disorders, and other major conditions. Innovent has a vertically integrated R&D and manufacturing platform with over 140,000L of total production capacity and more than 5,600 employees. The company has strategic collaborations with Eli Lilly, Roche, Sanofi, and Incyte. Innovent went public on the Hong Kong Stock Exchange in 2018.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account